ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 5, 2016, Pages 729-747

  Wollenberg, A ^a   Oranje, A ^b   Deleuran, M ^c   Simon, D ^d   Szalai, Z ^e   Kunz, B ^f   Svensson, A ^g   Barbarot, S ^h   Von Kobyletzki, L ^g   Taieb, A ⁱ   De Bruin Weller, M ^j   Werfel, T ^k   Trzeciak, M ^l   Vestergard, C ^c   Ring, J ^m,n   Darsow, U ^m  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dermicis Skin Clinic   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF BERN   (Switzerland)

^e HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^f Dermatologikum   (Germany)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITÉ DE NANTES   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j UTRECHT UNIVERSITY   (Netherlands)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l MEDICAL UNIVERSITY OF GDANSK   (Poland)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; APREMILAST; AZATHIOPRINE; BIOLOGICAL FACTOR; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; EMOLLIENT AGENT; FOOD ALLERGEN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; PIMECROLIMUS; PROBIOTIC AGENT; TACROLIMUS; VITAMIN;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; ATOPIC DERMATITIS; BANDAGING TECHNIQUE; CONTACT ALLERGY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; ECZEMA; ECZEMA MOLLUSCATUM; FOOD ALLERGY; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KAPOSI VARICELLIFORM ERUPTION; MATERNAL EXPOSURE; MICROBIAL COLONIZATION; PATERNAL EXPOSURE; PATIENT COUNSELING; PATIENT EDUCATION; PHOTOTHERAPY; PREGNANCY; PRIORITY JOURNAL; PRURITUS; SKIN CARE; SKIN DEFECT; STRESS; SUPERINFECTION; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; WET WRAP TREATMENT; ADULT; CHILD; DERMATITIS, ATOPIC; PRACTICE GUIDELINE;

ADULT; CHILD; DERMATITIS, ATOPIC; HUMANS;

EID: 84961794783     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13599     Document Type: Article

References (182)

1. Darsow U, Lubbe J, Taieb A, et al,. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-295.
2. Darsow U, Wollenberg A, Simon D, et al,. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-328.
3. Ring J, Alomar A, Bieber T, et al,. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060.
4. Ring J, Alomar A, Bieber T, et al,. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-1193.
5. Ring J, Przybilla B, Ruzicka T,. Handbook of Atopic Eczema. 2nd Edition, Berlin, Springer, 2005.
6. Johansson SGO, Bieber T, Dahl R, et al,. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836.
7. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wüthrich B,. Epidemiology, clinical features, and immunology of the 'intrinsic' (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-849.
8. Schultz-Larsen F,. Atopic dermatitis. Etiological studies based on a twin population. Kopenhagen, Laegeforeningens, 1985.
9. Weidinger S, Illig T, Baurecht H, et al,. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118: 214-219.
10. Ezzedine K, Droitcourt C, Ged C, et al,. Usefulness of a global clinical ichthyosis vulgaris scoring system for predicting common FLG null mutations in an adult caucasian population. Br J Dermatol 2012; 167: 1165-1169.
11. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; Suppl. 92: 44-47.
12. Williams HC,. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ 2007; 334: 1272.
13. Wollenberg A, Bieber T,. Proactive therapy of atopic dermatitis-an emerging concept. Allergy 2009; 64: 276-278.
14. European Task Force on Atopic Dermatitis. Severity Scoring of Atopic Dermatitis: the SCORAD Index. Dermatology 1993; 186: 23-31.
15. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A,. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
16. Langan SM, Schmitt J, Williams HC, Smith S, Thomas KS,. How are eczema 'flares' defined? A systematic review and recommendation for future studies. Br J Dermatol 2014; 170: 548-556.
17. Stalder JF, Barbarot S, Wollenberg A, et al,. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011; 66: 1114-1121.
18. Taïeb A,. Dermatite atopique: définition, épidémiologie, histoire naturelle, scores de gravité. Ann Dermatol Venereol 2005; 132: 1535-1543.
19. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C,. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-428.
20. Wollenberg A, Ehmann LM,. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24: 253-260.
21. Gelmetti C, Wollenberg A,. Atopic dermatitis-all you can do from the outside. Br J Dermatol 2014; 170 (Suppl 1): 19-24.
22. Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F, Gelmetti C,. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. J Eur Acad Dermatol Venereol 2009; 23: 751-759.
23. Koutroulis I, Pyle T, Kopylov D, Little A, Gaughan J, Kratimenos P,. The Association Between Bathing Habits and Severity of Atopic Dermatitis in Children. Clin Pediatr (Phila) 2016; 55: 176-181.
24. Åkerström U, Reitamo S, Langeland T, et al,. Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: a Randomized Double-blind Controlled Multicentre Clinical Trial. Acta Derm Venereol 2015; 95: 587-592.
25. Simpson EL, Chalmers JR, Hanifin JM, et al,. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-823.
26. Gueniche A, Knaudt B, Schuck E, et al,. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159: 1357-1363.
27. Boussault P, Léauté-Labrèze C, Saubusse E, et al,. Oat sensitization in children with atopic dermatitis: prevalence, risks and associated factors. Allergy 2007; 62: 1251-1256.
28. Breuer K, Wulf A, Constien A, Tetau D, Kapp A, Werfel T,. Birch pollen-related food as a provocation factor of allergic symptoms in children with atopic eczema/dermatitis syndrome. Allergy 2004; 59: 988-994.
29. Eigenmann P, Sicherer S, Borkowski T, Cohen B, Sampson H,. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101: E8.
30. Bath-Hextall F, Delamere FM, Williams HC,. Dietary exclusions for improving established atopic eczema in adults and children: systematic review. Allergy 2009; 64: 258-264.
31. Sinagra JL, Bordignon V, Ferraro C, et al,. Unnecessary milk elimination diets in children with atopic dermatitis. Pediatr Dermatol 2007; 24: 1-6.
32. Oranje A, Bruynzeel D, Stenveld H, Dieges P,. Immediate- and delayed-type contact hypersensitivity in children older than 5 years with atopic dermatitis: a pilot study comparing different tests. Pediatr Dermatol 1994; 11: 209-215.
33. Wollenberg A, Vogel S,. Patch testing for noncontact dermatitis: the atopy patch test for food and inhalants. Curr Allergy Asthma Rep 2013; 13: 539-544.
34. Turjanmaa K, Darsow U, Niggemann B, Rancé F, Vanto T, Werfel T,. EAACI/GA2LEN Position Paper: present status of the atopy patch test-position paper of the Section on Dermatology and the Section on Pediatrics of the EAACI. Allergy 2006; 61: 1377-1384.
35. Roehr CC, Reibel S, Ziegert M, Sommerfeld C, Wahn U, Niggemann B,. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 548-553.
36. Seidenari S, Giusti F, Bertoni L, Mantovani L,. Combined skin and patch testing enhances identification of peanut-allergic patients with atopic dermatitis. Allergy 2003; 58: 495-499.
37. Kerschenlohr K, Darsow U, Burgdorf WHC, Ring J, Wollenberg A,. Lessons of Atopy Patch Testing in Atopic Dermatitis. Curr Allergy Asthma Rep 2004; 4: 285-289.
38. Breuer K, Heratizadeh A, Wulf A, et al,. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004; 34: 817-824.
39. Werfel T, Heratizadeh A, Niebuhr M, et al,. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96-103, e109.
40. Garritsen FM, ter Haar NM, Spuls PI,. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. Br J Dermatol 2013; 168: 688-691.
41. Darsow U, Laifaoui J, Kerschenlohr K, et al,. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004; 59: 1318-1325.
42. Kerschenlohr K, Decard S, Darsow U, Ollert M, Wollenberg A,. Clinical and immunologic reactivity to aeroallergens in 'intrinsic' atopic dermatitis patients. J Allergy Clin Immunol 2003; 111: 195-197.
43. Herro EM, Matiz C, Sullivan K, Hamann C, Jacob SE,. Frequency of contact allergens in pediatric patients with atopic dermatitis. J Clin Aesthet Dermatol 2011; 4: 39-41.
44. Arkwright PD, Motala C, Subramanian H, et al,. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract 2013; 1: 142-151.
45. Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A,. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. J Eur Acad Dermatol Venereol 2015; 29: 1071-1081.
46. Isaksson M, Olhardt S, Rådehed J, Svensson A,. Children with atopic dermatitis should always be patch-tested if they have hand or foot dermatitis. Acta Derm Venereol 2015; 95: 583-586.
47. Seidenari S, Giusti F,. Skin sensitivity, interindividual factors: atopy. In, van deer Valk PMG, Maibach HI, eds. The irritant contact dermatitis syndrome. Boca Raton, CRC Press, Boca Raton, FL, 2006: 266.
48. Devillers AC, Oranje AP,. Wet-wrap treatment in children with atopic dermatitis: a practical guideline. Pediatr Dermatol 2012; 29: 24-27.
49. Janmohamed SR, Oranje AP, Devillers AC, et al,. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014; 70: 1076-1082.
50. Wollenberg A, Schnopp C,. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 351-368.
51. Niedner R,. Therapie mit systemischen Glukokortikoiden. Hautarzt 2001; 52: 1062-1071.
52. Walsh P, Aeling JL, Huff L, Weston WL,. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29: 501-503.
53. Eichenfield LF, Hanifin JM, Beck LA, et al,. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003; 111: 608-616.
54. Bornhövd E, Burgdorf WHC, Wollenberg A,. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-743.
55. Ruzicka T, Bieber T, Schöpf E, et al,. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-821.
56. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD,. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-809.
57. Reitamo S, Wollenberg A, Schopf E, et al,. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
58. Meurer M, Fartasch M, Albrecht G, et al,. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372.
59. Wollenberg A, Reitamo S, Atzori F, et al,. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742-750.
60. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al,. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-1356.
61. Reitamo S, Rustin M, Ruzicka T, et al,. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-555.
62. Luger T, Van-Leent EJ, Graeber M, et al,. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-794.
63. Thaci D, Salgo R,. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52-56.
64. Luger T, Boguniewicz M, Carr W, et al,. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 2015; 26: 306-315.
65. Bornhövd EC, Burgdorf WHC, Wollenberg A,. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002; 3: 708-712.
66. Lübbe J, Pournaras CC, Saurat JH,. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000; 201: 249-251.
67. Wetzel S, Wollenberg A,. Eczema molluscatum in tacrolimus treated atopic dermatitis. Eur J Dermatol 2004; 14: 73-74.
68. Queille-Roussel C, Paul C, Duteil L, et al,. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
69. Reitamo S, Rissanen J, Remitz A, et al,. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
70. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF,. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
71. Margolis DJ, Hoffstad O, Bilker W,. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-295.
72. Sigurgeirsson B, Boznanski A, Todd G, et al,. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015; 135: 597-606.
73. Reitamo S, Van Leent EJ, Ho V, et al,. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
74. Mandelin JM, Rubins A, Remitz A, et al,. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:∗ a two-year open-label study. Int J Dermatol 2012; 51: 104-110.
75. Eichenfield LF, Lucky AW, Boguniewicz M, et al,. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
76. Ho VC, Gupta A, Kaufmann R, et al,. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-162.
77. Reitamo S, Rustin M, Harper J, et al,. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-951.
78. van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al,. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013; 123: 917-927.
79. Berth-Jones J, Damstra RJ, Golsch S, et al,. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003; 326: 1367.
80. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T,. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801-807.
81. Chittock J, Brown K, Cork MJ, Danby SG,. Comparing the Effect of a Twice-Weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Derm Venereol 2015; 95: 653-658.
82. Wollenberg A, Sidhu MK, Odeyemi I, et al,. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008; 159: 1322-1330.
83. Garritsen FM, Brouwer MW, Limpens J, Spuls PI,. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170: 501-513.
84. Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M,. Gene expression of cytokines in atopic eczema before and after ultraviolet al phototherapy. Br J Dermatol 2008; 158: 1117-1120.
85. Dotterud LK, Wilsgaard T, Vorland LH, Falk ES,. The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int J Circumpolar Health 2008; 67: 254-260.
86. Hong SP, Kim MJ, Jung MY, et al,. Biopositive effects of low-dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 2008; 128: 2880-2887.
87. Mavilia L, Mori M, Rossi R, Campolmi P,. Puglisi Guerra A, Lotti T. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol 2008; 143: 329-337.
88. Becker D, Langer E, Seemann M, et al,. Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS ONE 2011; 6: e20566.
89. Gambichler T, Othlinghaus N, Tomi NS, et al,. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160: 652-658.
90. Novak N, Bieber T, Hoffmann M, et al,. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 925-931 e924.
91. Darsow U,. Allergen-specific immunotherapy for atopic eczema-updated. Curr Opin Allergy Clin Immunol 2012; 12: 665-669.
92. Diepgen TL,. Early Treatment of the Atopic Child Study G. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002; 13: 278-286.
93. Thurmond RL,. The histamine H4 receptor: from orphan to the clinic. Front Pharmacol 2015; 6: 65.
94. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA,. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009; 129: 14-30.
95. Kong HH, Oh J, Deming C, et al,. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-859.
96. Thum D, Seidl HP, Hein R, Ring J, Andres C, Mempel M,. Current resistance patterns of Staphylococcus aureus towards topical antibiotics and relevant antiseptics in patients with atopic dermatitis and impetigo. J Dtsch Dermatol Ges 2013; 11: 875-878.
97. Bunikowski R, Mielke ME, Skarabis H, et al,. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000; 105: 814-819.
98. Wichmann K, Uter W, Weiss J, et al,. Isolation of alpha-toxin-producing Staphylococcus aureus from the skin of highly sensitized adult patients with severe atopic dermatitis. Br J Dermatol 2009; 161: 300-305.
99. Hauser C, Wuethrich B, Matter L, Wilhelm JA, Sonnabend W, Schopfer K,. Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica 1985; 170: 35-39.
100. Breuer K,. S HA, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002; 147: 55-61.
101. Leyden JJ, Kligman AM,. The case for steroid-antibiotic combinations. Br J Dermatol 1977; 96: 179-187.
102. Brockow K, Grabenhorst P, Abeck D, et al,. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology 1999; 199: 231-236.
103. Tan WP, Suresh S, Tey HL, Chiam LY, Goon AT,. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin Exp Dermatol 2010; 35: e109-e112.
104. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS,. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009; 123: e808-e814.
105. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC,. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 2011; 164: 12-26.
106. Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D,. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 2003; 207: 15-21.
107. Ricci G, Patrizi A, Mandrioli P, et al,. Evaluation of the antibacterial activity of a special silk textile in the treatment of atopic dermatitis. Dermatology 2006; 213: 224-227.
108. Jaeger T, Rothmaier M, Zander H, Ring J, Gutermuth J, Anliker MD,. Acid-coated textiles (pH 5.5-6.5)-a new therapeutic strategy for atopic eczema? Acta Derm Venereol 2015; 95: 659-663.
109. Pluut OA, Bianco C, Jakasa I, et al,. Percutaneous penetration of silver from a silver containing garment in healthy volunteers and patients with atopic dermatitis. Toxicol Lett 2015; 235: 116-122.
110. Darabi K, Hostetler SG, Bechtel MA, Zirwas M,. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009; 60: 125-136.
111. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K,. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001; 56: 512-517.
112. Mayser P, Kupfer J, Nemetz D, et al,. Treatment of head and neck dermatitis with ciclopiroxolamine cream-results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19: 153-158.
113. Wollenberg A, Wetzel S, Burgdorf WH, Haas J,. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667-674.
114. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B,. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
115. Stalder J, Fleury M, Sourisse M,. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131: 536-540.
116. Syed TA, Goswami J, Ahmadpour OA, Ahmad SA,. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998; 25: 309-313.
117. Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA,. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis 2015; 15: 190-195.
118. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J,. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133: 429-438.
119. Schmitt J, Schakel K, Folster-Holst R, et al,. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010; 162: 661-668.
120. van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS,. Serum Creatinine Levels During and After Long-term Treatment with Cyclosporin A in Patients with Severe Atopic Dermatitis. Acta Derm Venereol 2015; 95: 963-967.
121. van der Schaft J, Politiek K, van den Reek JM, et al,. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 2015; 172: 1621-1627.
122. Meggitt SJ, Gray JC, Reynolds NJ,. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367: 839-846.
123. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA,. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013; 145: 1007-1015 e1003.
124. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: e1621-e1625.
125. Caufield M, Tom WL,. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol 2013; 68: 29-35.
126. Waxweiler WT, Agans R, Morrell DS,. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol 2011; 28: 689-694.
127. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI,. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353-359.
128. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA,. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64: 1074-1084.
129. Heller M, Shin HT, Orlow SJ, Schaffer JV,. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157: 127-132.
130. Murray ML, Cohen JB,. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007; 32: 23-27.
131. Ruzicka T, Lynde CW, Jemec GB, et al,. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-817.
132. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A,. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 2010; 162: 217-218.
133. Samrao A, Berry TM, Goreshi R, Simpson EL,. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012; 148: 890-897.
134. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW,. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res. 2011; 3: 89-95.
135. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L,. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518-522.
136. Kasperkiewicz M, Schmidt E, Frambach Y, et al,. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011; 127: 267-270.
137. Murase JE, Heller MM, Butler DC,. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014; 70: 401. e401-414; quiz 415.
138. Simon D, Bieber T,. Systemic therapy of atopic dermatitis. Allergy 2014; 69: 5.
139. Werfel T, Biedermann T,. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch. Curr Opin Allergy Clin Immunol 2015; 15: 446-452.
140. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N,. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008; 122: 423-424.
141. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T,. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010; 24: 837-839.
142. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU,. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121: 122-128.
143. Sedivá A, Kayserová J, Vernerová E, et al,. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121: 1515-1516.
144. Oldhoff JM, Darsow U, Werfel T, et al,. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693-696.
145. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M,. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52: 522-526.
146. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S,. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005; 53: 358-359.
147. Ruiz-Villaverde R, Galán-Gutierrez M,. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr 2012; 103: 743-746.
148. Navarini AA, French LE, Hofbauer GF,. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128: 1128-1130.
149. Belloni B, Ziai M, Lim A, et al,. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225.
150. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G,. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8: 990-998.
151. Iyengar SR, Hoyte EG, Loza A, et al,. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013; 162: 89-93.
152. Toledo F, Silvestre JF, Munoz C,. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 2012; 26: 1325-1327.
153. Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, et al,. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013; 23: 190-196.
154. Beck LA, Thaci D, Hamilton JD, et al,. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.
155. Amestejani M, Salehi BS, Vasigh M, et al,. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. J Drugs Dermatol 2012; 11: 327-330.
156. Benson AA, Toh JA, Vernon N, Jariwala SP,. The role of vitamin D in the immunopathogenesis of allergic skin diseases. Allergy 2012; 67: 296-301.
157. Hata TR, Audish D, Kotol P, et al,. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol 2014; 28: 781-789.
158. Javanbakht MH, Keshavarz SA, Djalali M, et al,. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. J Dermatolog Treat 2011; 22: 144-150.
159. Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S,. Probiotics: effects on immunity. Am J Clin Nutr 2001; 73: 444-450.
160. Doege K, Grajecki D, Zyriax BC, Detinkina E,. Zu Eulenburg C, Buhling KJ. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood-a meta-analysis. Br J Nutr 2012; 107: 1-6.
161. Pelucchi C, Chatenoud L, Turati F, et al,. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology 2012; 23: 402-414.
162. Schimke LF, Sawalle-Belohradsky J, Roesler J, et al,. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol 2010; 126: 611-617 e611.
163. Langan SM, Silcocks P, Williams HC,. What causes flares of eczema in children? Br J Dermatol 2009; 161: 640-646.
164. Wood RA, Sicherer SH, Vickery BP, et al,. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 2013; 131: 805-812.
165. Chen MH, Su TP, Chen YS, et al,. Is atopy in early childhood a risk factor for ADHD and ASD? a longitudinal study. J Psychosom Res 2014; 77: 316-321.
166. Park JH, Choi YL, Namkung JH, et al,. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006; 155: 778-783.
167. Zeppa L, Bellini V, Lisi P,. Atopic dermatitis in adults. Dermatitis 2011; 22: 40-46.
168. Lowe AJ, Tang ML, Dharmage SC, et al,. A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates. BMC Dermatol 2012; 12: 3.
169. Hyssen JP, Linneberg A, Engkilde K, Menné T, Johansen JD,. Contact sensitization to common haptens is associated with atopic dermatitis: new insight. Br J Dermatol 2012; 166: 1255-1261.
170. Staab D, Diepgen TL, Fartasch M, et al,. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. Br Med J 2006; 332: 933-938.
171. Mason JM, Carr J, Buckley C, et al,. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol 2013; 13: 7.
172. Gabeff R, Assathiany R, Barbarot S, Salinier C, Stalder JF,. Dermatite atopique: evaluation de la perception d'un plan d'action personnalise aupres de pediatres liberaux. Arch Pediatr 2014; 21: 705-708.
173. Proudfoot LE, Powell AM, Ayis S, et al,. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169: 901-909.
174. Deo M, Yung A, Hill S, Rademaker M,. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol 2014; 53: 1037-1041.
175. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B,. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013; 172: 351-356.
176. James JM, Burks AW, Roberson PK, Sampson HA,. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262-1266.
177. Mancini AJ, Paller AS, Simpson EL, Ellis CN, Eichenfield LF,. Improving the patient-clinician and parent-clinician partnership in atopic dermatitis management. Semin Cutan Med Surg 2012; 31: S23-S28.
178. van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, et al,. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. Br J Dermatol 2012; 166: 1060-1068.
179. Kupfer J, Gieler U, Diepgen TL, et al,. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J Psychosom Res 2010; 68: 353-358.
180. Schut C, Mahmutovic V, Gieler U, Kupfer J,. Patient education programs for childhood atopic dermatitis: who is interested? J Dtsch Dermatol Ges 2012; 10: 657-661.
181. Barbarot S, Bernier C, Deleuran M, et al,. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol 2013; 30: 199-206.
182. Stalder JF, Bernier C, Ball A, et al,. Therapeutic patient education in atopic dermatitis: worldwide experiences. Pediatr Dermatol 2013; 30: 329-334.